Cannabinol - Sativex
Sist oppdatert: Sist revidert:
Sist revidert av:Åse Mygland
- Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6. PMID: 17355549 PubMed
- Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O'Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9. PMID: 20307378 PubMed
- Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-1131. PMID: 21362108 PubMed
- F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavita, R Bruno Bossio, V Brescia Morra, G F Costantino, P Cavalla, D Centonze, G Comi, S Cottone, M Danni, A Francia, A Gajofatto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosu, M Matta, M Mirabella, E Montanari, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentino, M Zappia. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016 Sep; 87(9): 944–95. PMID: 27160523 PubMed
- Freidel M1, Tiel-Wilck K, Schreiber H, Prechtl A, Essner U, Lang M.. Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability. Acta Neurol Scand. 2014. pmid:25208898 PubMed
- Åse Mygland, spesialist i nevrologi, professor dr med
- Unn Ljøstad, spesialist i nevrologi, professor PhD